New research presented at the American Society of Hematology Annual Meeting reveals promising results for tipifarnib, a potential treatment for acute myeloid leukemia (AML) in elderly patients. The study found molecular predictors of response to tipifarnib, offering hope for improved patient outcomes.
The study demonstrates the value of clinical cutoffs in evaluating HIV drug resistance information. Clinical cutoffs based on a large outcomes database provide physicians with clinically relevant resistance information.
The study found that patients treated with DOXIL had a median overall survival of 63 weeks, compared to 60 weeks with topotecan. Additionally, DOXIL showed significant advantages in progression-free survival and median PFS for platinum-sensitive patients.
Mt. Sinai researchers found that aspirin significantly reduces the risk of a first heart attack in apparently healthy individuals by one-third. The study's findings support treatment guidelines issued by the American Heart Association and U.S. Preventive Services Task Force, recommending aspirin use for those at high risk.
A Phase II study found that the DVd regimen showed a high response rate of 88%, with 12% achieving complete response. The treatment was well-tolerated, with the most common Grade 3 or 4 toxicity being palmar-plantar erythrodysesthesia. Improved patient education and prevention measures reduced toxicity incidence.
A meta-analysis of randomized trials confirms that aspirin significantly reduces first heart attack risk and combined cardiovascular events. The study supports recent guidelines recommending aspirin therapy for individuals with a 10% or greater 10-year coronary event risk.
A new study by Eckehard Liske, PhD, confirms the safety and efficacy of RemiFemin in relieving menopausal symptoms. The research shows that standardized herbal supplement works without affecting hormone levels, reducing hot flashes, mood swings, night sweats, and sleeplessness.
Researchers discovered that STI-HAART can train the immune system to control HIV by developing a stronger response against the virus. The study provides a potential recipe for further research on restoring HIV-specific immunity after acute infection.